<DOC>
	<DOCNO>NCT00129441</DOCNO>
	<brief_summary>The purpose research study determine whether short-term administration investigational study drug may provide evidence improvement cognitive function group stable male subject schizophrenia .</brief_summary>
	<brief_title>Gamma-Amino Butyric Acid ( GABA ) -A Alpha2/3 Study</brief_title>
	<detailed_description>The goal study determine whether short-term ( 4 week ) , double-blind administration Merck L-830982 provide evidence improvement cognitive functioning stable male subject schizophrenia . This initial , small sample size study ( n=9 L-830982 n=6 placebo ) restrict male order reduce variance might attributable well-documented sex difference clinical feature schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Male participant Between age 18 50 Meet diagnostic criterion schizophrenia schizoaffective disorder Are clinically stable minimum 3 month current dose medication Are unemployed ( i.e. , work le 20 hour per week competitive employment ) Psychoactive substance dependence within past 6 month substance abuse within past month History head trauma neurological disorder Medical illness medication , benzodiazepine treatment HIV medication , may affect study participation ( study doctor discuss potential subject ) Mental retardation Seizure disorder History heart attack , arrhythmia , heart disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>schizophrenia</keyword>
</DOC>